Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

Last updated: June 1, 2018
Sponsor: Dong-A Pharmaceutical
Overall Status: Active - Recruiting

Phase

4

Condition

Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT03542721
DA-5515
  • Ages 19-79
  • All Genders

Study Summary

The aim of the present clinical study is to evaluate the efficacy and safety of the DA-5515 (Circulan Soft Cap.) in patients with chronic fatigue symptoms due to impaired blood circulation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Rutherford's category 0/0 or Ⅰ/1

  • ABI <1.0

  • CIS greater than 76

  • HADS less than or equal to 10

  • Subjects who have fatigue symptoms more than 1 month

Exclusion

Exclusion Criteria:

  • Subjects who have diseases that can cause fatigue

  • Subjects who are taking medication that can cause fatigue

Study Design

Total Participants: 204
Study Start date:
January 17, 2018
Estimated Completion Date:
December 31, 2019

Study Description

This study is conducting to assess the efficacy and safety of the DA-5515 (Circulan Soft Cap.), which has been known to have a fatigue recovery effect due to impaired blood circulation.

Connect with a study center

  • Seoul St. Mary's Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.